Parmax Pharma Stock Price Analysis and Quick Research Report. Is Parmax Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Parmax Pharma. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Parmax Pharma has a PE ratio of -2.29364326375712 which is low and comparatively undervalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Parmax Pharma has ROA of -12.3582% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Parmax Pharma has a Current ratio of 0.7672.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Parmax Pharma has a ROE of 0%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Parmax Pharma has a Debt to Equity ratio of -4.0673 which means that the company has low proportion of debt in its capital.

• Sales growth: Parmax Pharma has reported revenue growth of 155.1694% which is fair in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Parmax Pharma for the current financial year is 0.902930023206849%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Parmax Pharma is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Parmax Pharma is Rs -12.648. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Parmax Pharma in Ticker for free. Also, one can get the intrinsic value of Parmax Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Parmax Pharma FAQs

Q1. What is Parmax Pharma share price today?
Ans: The current share price of Parmax Pharma is Rs 29.01.

Q2. What is the market capitalisation of Parmax Pharma?
Ans: Parmax Pharma has a market capitalisation of Rs 10.8535113 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Parmax Pharma?
Ans: The PE ratio of Parmax Pharma is -2.29364326375712 and the P/B ratio of Parmax Pharma is -1.95857356972144, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Parmax Pharma share?
Ans: The 52-week high share price of Parmax Pharma is Rs 55.02, and the 52-week low share price of Parmax Pharma is Rs 28.

Q5. Does Parmax Pharma pay dividends?
Ans: Currently, Parmax Pharma does not pay dividends. Dividend yield of Parmax Pharma is around 0%.

Q6. What are the face value and book value of Parmax Pharma shares?
Ans: The face value of Parmax Pharma shares is Rs 10, while the book value per share of Parmax Pharma is around Rs -14.8118. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Parmax Pharma?
Ans: Parmax Pharma has a total debt of Rs 8.0885613 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Parmax Pharma?
Ans: The ROE of Parmax Pharma is 0% and ROCE of Parmax Pharma is -29.8782%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Parmax Pharma a good buy for the long term?
Ans: The Parmax Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Parmax Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Parmax Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Parmax Pharma’s financials?
Ans: You can review Parmax Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.